Clinical Study Number | 135.301 |
---|---|
Study Indication | Myocardial Infarction |
Product | ACTILYSE ® |
Generic Name | Alteplase |
Lab Code | |
Clinical Phase | IV |
Study Title |
A multicentre, feasibility study of pre-hospital treatment of acute myocardial infarction based on diagnosis by interpretation of remotely acquired ECG and thrombolysis with accelerated alteplase (Actilyse®). Pre-Hospital Alteplase Remote Advice Of Hospital (PHARAOH) |
Study Document | Trial synopsis 135.301 english |
Clinical Study Number | 1123.12 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IIIb, IV |
Study Title |
A phase IIIb - IV, randomised, open label trial evaluating the efficacy and safety of tenecteplase together with unfractionated heparin prior to early PCI as compared to standard primary PCI in patients with acute myocardial infarction.(ASSENT 4 PCI) (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.) |
Study Document | Trial Statement 1123.12_CO english Trial synopsis 1123.12_CO english |
Clinical Study Number | 1123.25 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IV |
Study Title |
Post Marketing Surveillance to monitor the safety and efficacy of Metalyse® (Tenecteplase) in Korean patients with Acute Myocardial Infarction |
Study Document | Trial synopsis 1123.25_CO english |
Clinical Study Number | 1123.22 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IV |
Study Title |
A Post Registration Therapeutic Observational Study of Metalyse® in Patients with Acute Myocardial Infarction in the Russian Federation |
Study Document | Trial synopsis 1123.22_CO english |
Clinical Study Number | 1123.28 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IIIb/V |
Study Title |
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the efficacy and safety of a strategy of early fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours or rescue coronary intervention versus a strategy of standard primary PCI in patients with acute myocardial infarction within 3 hours of onset of symptoms |
Study Document | Trial synopsis 1123.28 english |
Clinical Study Number | 1123.5 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IIIb |
Study Title |
An open-label, randomised, parallel-group comparison to investigate the procoagulant effect of tenecteplase (TNK-tPA), alteplase (rt-PA) and streptokinase (SK) administered to patients with AMI. |
Study Document | Trial synopsis 1123.5 english |
Clinical Study Number | 1123.11 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IIIb/IV |
Study Title |
A phase IIIb-IV, randomised, open label trial on efficacy and safety of 2 parallel groups: full dose tenecteplase combined with unfractionated heparin orenoxaparin in acute myocardial infarction in the prehospital setting (ASSENT 3Plus) ASSENT 3 Plus was a satellite study to ASSENT 3 (main study). ASSENT (ASsessment of the Safety and Efficacy of New Thrombolyticregimens) |
Study Document | Trial synopsis 1123.11_CO english |
Clinical Study Number | 1123.10 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IIIb |
Study Title |
A phase IIIb, randomised, open label trial with 3 parallel groups: fulldose TNK-tPA together with heparin sodium, full dose TNK-tPA together with enoxaparin, and half dose TNK-tPA together with abciximab and heparin sodium in patients with acute myocardial infarction: ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic regimen). |
Study Document | Trial synopsis 1123.10_CO english |
Clinical Study Number | 1123.16 |
---|---|
Study Indication | Myocardial Infarction |
Product | METALYSE ® |
Generic Name | Tenecteplase |
Lab Code | |
Clinical Phase | IV |
Study Title |
Surveillance of patients with suspected acute myocardial infarction that receive prehospital or early in hospital (emergency department) thrombolysis with Metalyse®. |
Study Document | Trial synopsis 1123.16 english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.